Details

Autor(en) / Beteiligte

• Jones, Bryan E
• Brown-Augsburger, Patricia L
• Corbett, Kizzmekia S
• Westendorf, Kathryn
• Davies, Julian
• Cujec, Thomas P
• Wiethoff, Christopher M
• Blackbourne, Jamie L
• Heinz, Beverly A
• Foster, Denisa
• Higgs, Richard E
• Balasubramaniam, Deepa
• Wang, Lingshu
• Zhang, Yi
• Yang, Eun Sung
• Bidshahri, Roza
• Kraft, Lucas
• Hwang, Yuri
• Žentelis, Stefanie
• Jepson, Kevin R
• Goya, Rodrigo
• Smith, Maia A
• Collins, David W
• Hinshaw, Samuel J
• Tycho, Sean A
• Pellacani, Davide
• Xiang, Ping
• Muthuraman, Krithika
• Sobhanifar, Solmaz
• Piper, Marissa H
• Triana, Franz J
• Hendle, Jorg
• Pustilnik, Anna
• Adams, Andrew C
• Berens, Shawn J
• Baric, Ralph S
• Martinez, David R
• Cross, Robert W
• Geisbert, Thomas W
• Borisevich, Viktoriya
• Abiona, Olubukola
• Belli, Hayley M
• de Vries, Maren
• Mohamed, Adil
• Dittmann, Meike
• Samanovic, Marie I
• Mulligan, Mark J
• Goldsmith, Jory A
• Hsieh, Ching-Lin
• Johnson, Nicole V
• Wrapp, Daniel
• McLellan, Jason S
• Barnhart, Bryan C
• Graham, Barney S
• Mascola, John R
• Hansen, Carl L
• Falconer, Ester

Titel

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

Ist Teil von

• Science translational medicine, 2021-05, Vol.13 (593)

Ort / Verlag

United States

Erscheinungsjahr

2021

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may bridge widespread vaccination campaigns and offer a treatment solution in populations less responsive to vaccination. Here, we report that high-throughput microfluidic screening of antigen-specific B cells led to the identification of LY-CoV555 (also known as bamlanivimab), a potent anti-spike neutralizing antibody from a hospitalized, convalescent patient with coronavirus disease 2019 (COVID-19). Biochemical, structural, and functional characterization of LY-CoV555 revealed high-affinity binding to the receptor-binding domain, angiotensin-converting enzyme 2 binding inhibition, and potent neutralizing activity. A pharmacokinetic study of LY-CoV555 conducted in cynomolgus monkeys demonstrated a mean half-life of 13 days and a clearance of 0.22 ml hour kg , consistent with a typical human therapeutic antibody. In a rhesus macaque challenge model, prophylactic doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract in samples collected through study day 6 after viral inoculation. This antibody has entered clinical testing and is being evaluated across a spectrum of COVID-19 indications, including prevention and treatment.